Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
2016
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
13
Citations
NaN
KQI